Dubrovsky E, et al. - Using the National Cancer Database (NCDB) that includes 6227 cases age (18-90) of pathologic T1/T2 and N0/N1 male breast cancer (MBC) with known genomic testing status, researchers investigated the current national trends of genomic testing in MBC. Further, they determined how the genomic testing is associated with systemic therapy. Genomic testing was undertaken in 1478 (23.74%) cases of MBC. Age, race, tumor grade, year of diagnosis, receptor status, and nodal status were noted significantly influencing the testing. Men and women with early stage invasive breast cancer had similar rates of testing and distribution of risk of recurrence scores (RRS). They noted the significant association of RRS in men with tumor grade and size, but not nodal status. Seven-times higher likelihood to be treated with hormone therapy alone was observed for those with a low RRS. A combination of hormone and chemotherapy was five times more likely in those with a high RRS.